Current Report Filing (8-k)
27 April 2018 - 4:17AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
April
19, 2018
ADVANCED
BIOMEDICAL TECHNOLOGIES INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
000-53051
|
|
98-0516589
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
3842-Orthopedic,
Prosthetic, & Surgical
Appliances & Supplies
|
|
0001385799
|
(Standard
Industrial Classification)
|
|
(Central
Index Key)
|
350
Fifth Avenue, 59th Floor
New
York, NY 10118
(Address
of principal executive offices, including zip code)
(718)
766-7898
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report.)
Copy
of Communication to:
Befumo
& Schaeffer, PLLC
PO
Box 717
Culpeper,
VA 22701
Phone:
(202) 725-6733
Fax:
(202) 478-2900
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
8.01 Other Events
On
April 19, 2018, Advanced Biomedical Technologies, Inc. (the “Company”) issued a press release announcing that it had
received approval from the Chinese Food and Drug Administration (“CFDA”) for the polymer orthopaedic internal fixation
screws (“PA Screws”) developed by the Company’s subsidiary Shenzhen Changhua Biomedical Engineering Company
Limited. PA Screws consist of PA6-P(MMA-CO-NVP)-HA, an innovative unique material developed by the Company. The CFDA approval
marked a milestone in the Company’s history and presents the Company with great clinical and financial potential, as series
of new products are based on the same unique material.
Attached
to this Current Report on Form 8-K is the press release issued by the Company announcing the approval from the CFDA for PA Screws.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
April 26, 2018
|
ADVANCED
BIOMEDICAL TECHNOLOGIES, INC.
|
|
|
|
/s/
Kai Gui
|
|
Kai
Gui
|
|
Chief
Financial Officer, Chief Operating Officer
|
Advanced BioMedical Tech... (CE) (USOTC:ABMT)
Historical Stock Chart
From Jan 2025 to Feb 2025
Advanced BioMedical Tech... (CE) (USOTC:ABMT)
Historical Stock Chart
From Feb 2024 to Feb 2025
Real-Time news about Advanced BioMedical Technologies Inc (CE) (OTCMarkets): 0 recent articles
More Advanced Biomedical Technologies Inc. News Articles